Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets slip
Tue, 22 Jan 01:30 pm

Indian equity markets pared early gains and slipped in the red in the post noon trading session. Barring banking, all the sectoral indices are trading negative with consumer durables, realty and IT being the biggest losers.

BSE-Sensex is down 10 points and NSE-Nifty is trading down marginally. While BSE Mid Cap is down marginally, BSE Small Cap index is trading flat. The rupee is trading at 53.4 to the US dollar.

Majority of the hotel stocks are trading in green with Hotel Leelaventure and Indian Hotels being the biggest gainers. However, Oriental Hotels and EIH Ltd are trading in the red. According to a leading financial daily, the Reserve Bank of India (RBI) has permitted domestic hotel companies to tap external commercial borrowings (ECB) for their funding requirements. The ECB route can be resorted to by hotel companies in case of project size of at least Rs 2.5 bn and in any geographical location. The ECBs can be availed by companies either to repay outstanding rupee loans or for fresh rupee capital expenditure. As per existing guidelines, only companies operating in manufacturing and infrastructure sectors and with significant foreign exchange earnings were allowed to take ECBs. In September 2012, RBI had raised the maximum permissible ECB limit from 50% to 75% of average foreign exchange earnings in the past three years with the maximum ceiling fixed at US$ 3 bn.

Pharma stocks are trading mixed with Sun Pharma and Jubilant Lifescience being among the leading gainers and Dishman Pharma and Panacea Biotech being among the top underperformers. Lupin Ltd received approval for one more oral contraceptive drug, Lovonogrestel and Ethinyl Estradiol usp 0.mg/0.02mg from USFDA. The said approval is the generic version of Watson's drug Lutera 28 Tablets. The brand size of this drug is US$ 103 m. The company will soon launch the drug in the US. Lupin already holds six approvals in the oral contraceptive space and targets to widen the oral contraceptive portfolio by making similar launches in the future. The stock was trading down by 0.6%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets slip". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.